

OCTOBER 2010

CURRICULUM VITAE

DR DANIEL ALBERTO VOROBIOF

Date of Birth: September 15, 1949
 Place of Birth: Santa Fe, Argentina
 Marital Status: Married (Michal, art teacher) with 2 children (Gabriel (1974), MBChB Wits),
 Edva Rachel (1977), BA (Honours) (Psych),
 Spoken Languages: Fluently: Spanish, English, Hebrew
 Less Fluent: Afrikaans, Portuguese, Italian

SCHOOL EDUCATION

1955-1961: Primary School, Santa Fe, Argentina
 1962-1966: Commercial High School, Santa Fe, Argentina

MEDICAL EDUCATION AND EXPERIENCE

1967-1972 Medical Studies, School of Medicine, Faculty of Health Sciences, University of Cordoba, Argentina

Dec. 1972: Medical Doctor Diploma (Medico Cirujano, University of Cordoba, Argentina)

Feb-May 1973: Intern, Clinicas Hospital, Internal Medicine Depart., University of Cordoba, Argentina

Dec.73-Jan 1975: Internship, Soroka Medical Centre, BenGurion University, Beersheba, Israel

Feb.75-July 1980: Internal Medicine Residency, Dept. of Internal Medicine C, Soroka Medical Centre, BenGurion University, Beersheba, Israel

1976-1977: Instructor in Internal Medicine to General Practitioners of peripheral clinics; National Health Insurance Ass. and the Hebrew University of Jerusalem, Israel

1976-1980: Instructor in Internal Medicine, School of Medicine, BenGurion University of Negev, Beersheba, Israel

1977: Instructor in two "General Medicine in Israel" courses to new immigrant medical doctors, Beersheba Centre of Absorption, Israel

1977: Recipient of a grant from the Batscheva de Rotschild Fund to young investigators

1977-1980: General Practitioner (part time) at Kibbutz Bror Chail, Negev, Israel

Aug 1980-1982: Clinical Assistant, Medical Oncology Department, H F Verwoerd Hospital, Pretoria, South Africa

1983-March 87: Senior Medical Officer, Medical Oncology Department, H F Verwoerd Hospital, Pretoria

April 87-Jan 1989: Specialist Physician, Medical Oncology Department, H F Verwoerd Hospital, Pretoria

- April 87-Jan 1989: Senior Lecturer, Faculty of Medicine, University of Pretoria, Pretoria
- Feb 89-June 1989: Specialist Physician, Internal Medicine Department, Johannesburg Hospital, Johannesburg
- July 1989-1995: Part time consultant at: Breast Cancer Clinic, Johannesburg Hospital and Gynaecology-Oncology Clinic, Hillbrow Hospital
- July 1989-to date: Private Practice (Specialist Physician/Medical Oncologist) at the Sandton Oncology Centre, Johannesburg.
- April 1992-to date: Director of Sandton Oncology Centre, Johannesburg
- April 1992- to date: Researcher and Director Sandton Oncology Medical Research, Johannesburg
Executive Member of International Affairs Committee, American Society of Clinical Oncology (ASCO)
- Feb.2000-todate: Co-Director Research, Development & Data Acquisition (RDDA) CRO, Johannesburg
- 2000-to date: External Examiner, College of Medicine, (Medical Oncology)
- 2001: Member of ASCO International Strategic Planning Task Force
- 2004-2007: Member of the Developing Countries Task Force (DCTF) (ESMO)
- 2005-2008: Regional Representative (Sub Sahara Africa) ESMO

REGISTERED SPECIALITIES (with Health Professional Council South Africa)

- April 1987: Specialist Physician
- January 1991: Medical Oncology

DOCTORAL THESIS

“Evaluation of radionuclide measurements of cardiac function in patients with cancer treated with Cytostatic Agents”. University of Pretoria, 1987.

AWARDS

Gynaecology Oncology Award, Univ. of Witwatersrand, 2008

PUBLICATIONS

1. Vorobiof D A, Biniamin J, Dvilansky A. Chronic Granulocytic Leukemia, Neutrophilic type with paraproteinemia (IgA type K). *Acta Haematologica* 60:316-320, 1978.
2. Vorobiof D A. 5-Fluorouracil Cardiotoxicity. A case report. *S A Med. Journal*: 633-634, 1982.
3. Falkson G, Vorobiof D A, Sinoff C L. Chemotherapy for Oral Malignant Disease. *Journ. Dental Assoc. of SA* 37:607-609, 1982.
4. Vorobiof D A, Falkson G. Metastatic Malignant Melanoma. *Cancer Therapy update* 2:8, 1982.
5. Vorobiof D A, Iturralde M, Falkson G. m-AMSA (NSC 249992) Cardiotoxicity: Assessment of Ventricular Function by Radionuclide Angiography. *Cancer Treat. Rep.* 67:1115-1117, 1983.
6. Falkson G, Vorobiof D A, Lerner H J. A phase 2 study of m-AMSA in patients with Malignant Mesothelioma. *Cancer Chemotherapy Pharmacol* 11:94-97, 1983.
7. Falkson G, Vorobiof D A. Epirubicin in Colorectal Cancer. In: *Advances in Anthracycline Chemotherapy: Epirubicin*. Ed: G Bonadonna, Masson Italia Editori, Milano, pp 105-109, 1984.
8. Vorobiof D A. Radionuclide Ventriculography for the Assessment of the Left Ventricular function in patients receiving cancer chemotherapy. *Cancer Therapy Update* 4:3, May-June, 1984.
9. Vorobiof D A, Falkson G. Modalidades Terapeuticas del Mesothelioma Maligno. *La Prensa Medica Argentina* 71:540-542, 1984.
10. Vorobiof D A. Report on an overseas visit to North and South America. *S A Cancer Bul.* 28:231-253, 1984.
11. Vorobiof D A, Thurlimann B J K, Falkson G. New therapy for Prostate Cancer. *Cancer Therapy Update*, Vol. V, No 5, Sept.-Oct. 1985.
12. Vorobiof D A, Iturralde M, Falkson G. Assessment of Ventricular function by Radionuclide Angiography in patients receiving 4-Epidoxorubicin and Mitoxantrone. *Cancer Chemotherapy Pharmacol.* 15:253-257, 1985.
13. Falkson G, Vorobiof D A. Phase II Study of 4-Deoxydoxorubicin in Advanced Colorectal Cancer *Invest. New Drugs* 4:165-169, 1986.
14. Falkson G, Coccia-Portugal M A, Vorobiof D A, Terblanche A P S, Dreyer R. Oral Idarubicin in combination with Cytosine-Arabinoside in previously untreated patients with Acute Non-Lymphocitic Leukemia. *Am. J of Clin. Oncol.* 9:311-314, 1986.
15. Falkson G, Iturralde M, Vorobiof D A. Assessment of Ventricular function of Radionuclide Angiography in patients receiving 4-Epidoxorubicin and Mitoxantrone. (Reply letters to the Editors) *Cancer Chemotherapy Pharmacol.* 17:296-297, 1986.
16. Vorobiof D A, Sarli R, Falkson G. Combination chemotherapy with DTIC and Vindesine in the treatment of Metastatic Malignant Melanoma. *Cancer Treat. Rep.* 70:927-928.
17. Vorobiof D A, Falkson G. Nasally administered Buserelin inducing complete remission of lung metastases in male Breast Cancer. *Cancer* 59:688-689, 1987.
18. Falkson G, Vorobiof D A, Simpson I W, Borden E C. Phase II trial of Acivicin (AT-125) in Malignant Mesothelioma. *Cancer Treat Rep.* 71:545, 1987.
19. Iturralde M P, Vorobiof D A. Protection - The Heart of the Matter. *Nuclear Active* 37:14-17, 1987.

20. Falkson G, Vorobiof D A. Intranasal Buserelin in the treatment of advanced Prostate Cancer. A phase II trial. *J. Clin. Oncol.* 5:1419-1423, 1987.
21. Vorobiof D A, Falkson G, Coccia-Portugal M A, Terblanche A P S. Mitoxantrone in the treatment of Acute Leukemia. *Inv. New Drugs* 5:383-388, 1987.
22. Vorobiof D A, Iturralde M P. Ventriculografia nuclear en el control de pacientes tratados con Quimioterapia Anticancerosa. *Rev El Inst Cancerol (Mexico)* 33(4):459-462, 1987.
23. Vorobiof D A, Falkson G. New endocrine therapies for Prostate Cancer. *Indian J of Cancer CT* 9(2):61-63, 1987.
24. Alberts A S, Falkson G, Goedhals L, Vorobiof D A, van der Merwe C A. Malignant Pleural Mesothelioma. A disease unaffected by current therapeutic manoeuvres. An analyses of 262 patients. *J. Clin. Oncol.* 6:527-535, 1988.
25. Vorobiof D A, Terblanche A P S, Falkson G. Cyclophosphamide, Mitoxantrone, Vincristine and Prednisone in the treatment of Non-Hodgkin's Lymphoma. *Oncology* 45:378-379, 1988.
26. Vorobiof D A, Falkson G, Iturralde M P. Radionuclide angiographic monitoring in patients treated with potentially cardiotoxic cytostatic drugs. *S. A. Med. J.* 74:213-216, 1988.
27. Vorobiof D A, Chasen M R, Falkson G. Leptomeningeal metastases from stomach and ovarian carcinoma. *Indian J. of Cancer CT* 10(1) 25-29, 1988.
28. Vorobiof D A. Falkson G . Phase II study of high dose 4-Epidoxorubicin in the treatment of advanced gastrointestinal cancer. *Eur. J Cancer* 24:563-564, 1989.
29. Vorobiof D A. Interferon Alpha 2B. *Integument* 3(3):7-8, 1989.
30. Vorobiof D A. Basic principles of medical oncology. *Understanding Oncol.* 1:8-10, 1990.
31. Vorobiof D A, Jersky J. Principles of surgical oncology. *Understanding Oncol.* 1:12-13, 1990.
32. Vorobiof D A. The clinical oncologic problem. *Understanding Oncol.* 1:27-32, 1990.
33. Vorobiof D A. Clinical pharmacology of cancer. *Understanding Oncol.* 2:7-9, 1990.
34. Vorobiof D A. Prostate Cancer - a disease of the older generation. *Hospital Medicine XII(7):*18, 1990.
35. Vorobiof D A. Chemotherapy in adjuvant and metastatic Colorectal Cancers. *Understanding Oncol.* 2(3)19-24, 1991.
36. Vorobiof D A. The medical therapy of metastatic Malignant Melanoma. *Diseases of the skin* 5(4) 13-15, 1991.
37. Vorobiof D A. Can cancer be beaten? Letter to the Editor. *SAMJ* 81(4) 228, 1992.
38. Vorobiof D A. The chemotherapy treatment of locally advanced and metastatic Bladder Cancer. *Understanding Oncol.* 3(2) 29-34, 1992.
39. Vorobiof D A. Early diagnosis, prevention of gynaecological cancers. *Medicine Today* 2(11) 46, 1992.
40. Vorobiof D A. Testicular Cancer - the medical treatment. *Understanding Oncol.* 3(3) 11-15, 1992.
41. Vorobiof D A. Chemotherapy agents used in the treatment of Haematologic Malignancies. *Understanding Oncol.* 4(1) 18-34, 1993.

42. Ruff P, Paska W, Goedhals L, Pouillart P, Rivierre A, Vorobiof D A, Bloch B , Jones A, Martin C, Brunet R, Butcher M, Foster J. Ondansetron compared to granisetron in the prophylaxis of Cisplatin-induced acute emesis: A multi-centre, double blind, randomised, parallel group study. *Oncology* 51:113-118, 1994.
43. Vorobiof D A, Bezwoda W R. A randomised trial of Vindesine plus Interferon Alfa 2B or Vindesine alone in the treatment of Advanced Malignant Melanoma. *European Journal of Cancer*, Vol.30A, no.6, pp.797-800, 1994.
44. Vorobiof D A. Recent advances in the treatment of Malignant Melanoma. *Melanoma Update* 1: 1-4, 1995.
45. Vorobiof D A. Therapeutic modalities of Malignant Pleural Mesothelioma. *Understanding Oncol.* 6(2) 14-16, 1995.
46. Vorobiof D A. Malignant Melanoma: Clinical characteristics and chemotherapy treatment. *Understanding Oncol.* 6(4) 8-14, 1995.
47. Arimidex Study Group. A randomised trial comparing two doses of the new selective aromatase inhibitor Anastrozole (Arimidex) with Megestrol Acetate in post menopausal patients with Advanced Breast Cancer. *Eur. J Cancer* 32A(3) 404-412, 1996
48. Abratt R, Vorobiof D A. Congress Report on European Conference on Clinical Oncology. *Understanding Oncol.* 7(1) 4-6, 1996.
49. Chasen M R, Vorobiof D A. Current treatment of Osteosarcoma and Soft Tissue Sarcomas. *Understanding Oncol.* 7(1) 18-20, 1996.
50. Chasen M R, Lindeque B, Vorobiof D A. Osteosarcoma, a therapeutic gain. *Hospital Update*, 1996.
51. Vorobiof D A. The medical treatment of Malignant Melanoma. *CME Journal* 14(10) 1505-1508, 1996.
52. Vorobiof D A. Chemotherapy in the treatment of Head and Neck Cancer. *Understanding Oncol.* 7(4), 1996.
53. Kleeberg U, Dowsett M, Carrion R P, Dodwell D J, Vorobiof D A, Aparicio L A, Robertson F J R. A randomized comparison of Oestrogen Suppression with Anastrozole and Formestane in Postmenopausal patients with Advanced Breast Cancer. *Oncology* 54 Suppl 2: 19-22, 1997.
54. Vorobiof D A. The potential use of biological response modifiers in older patients with cancer. *Specialist Medicine* XIX (3) 6-16, 1997.
55. Vorobiof D A. Metabolic, hematologic and infectious emergencies in cancer patients. *Understanding Oncology*, Vol. 8 (1) 7-12, 1997.
56. Chasen M R, Vorobiof D A. Chemotherapy of epithelial carcinoma of the ovary. *Understanding Oncology*, Vol. 8 (3) 35-38, 1997
57. Vorobiof D A. Chemotherapy treatment of Gynaecological cancers. *O & G Forum*. Vol 7 (4): 28-33, 1997.
58. Abratt R, Vorobiof D A Letter from South Africa. *Cancer Topics*. 10(8): 9, 1997.
59. Vorobiof D A, Chasen M R Common Cancers: Breast, Lung and Prostate cancers. *CME Journal*, 16(5): 393 - 403, 1998.

60. Vorobiof D A, Malignant Melanoma: Advances in treatment. *Diseases of the Skin* 12 (5) 7-10, 1998.
61. Chasen M R, Vorobiof D A, Palliative care for the terminally ill patient. *Disease Review*. Eds: J R Snyman, De K Sommers, MIMS, Pretoria, 580-583, 1999.
62. Chan S, Friedrichs K, Noel D, Pintér T, Van Belle S, Vorobiof D A, Duarte R, Gil Gil M, Bodrogi I, Murray E, Yelle L, Von Minckwitz G, Korec S, Simmonds P, Buzzi F, González Mancha R, Richardson G, Walpole E, Ronzoni M, Murawsky M, Alaki M, Riva A, Crown J. Prospective randomized trial of Docetaxel versus Doxorubicin in patients with metastatic Breast Cancer. *J Clin Oncol* 17:2341-2354, 1999.
63. Vorobiof D A, HRT and Breast Cancer – Letters to the Editor. *CME*. 17 (7): 658, 1999.
64. Goedhals L, Vorobiof D A, Bezwoda W, Van Der Merwe A, Jordaan JP, Barnardt P, Smith BL. Phase II trial of IV Vinorelbine and Cisplatin in inoperable locally advanced or disseminated Non-Small Cell Lung Cancer. The South African Experience. *Current Medical Research and Opinion*. 15 (3): 185-192, 1999.
65. Vorobiof D A, Kleeberg VR, Perez Carrion R, Dodwell DJ, Robertson JFR, Calvo L, Dowsett M, Clack G. A randomized open parallel group trial to compare the endocrine effects of oral Anastrozole (Arimidex) with intramuscular Formestane in post menopausal women with advanced Breast Cancer. *Annals of Oncology*. 10: 1219-1255, 1999.
66. Vorobiof DA, Abratt R, Rapoport B, Ruff P, Slabber C, Goedhals L. Scientific Misconduct in Cancer Clinical Trials. *S.A. Med. J.* 91 (8): 614-615, 2001.
67. Abratt RP, Vorobiof DA, Goedhals L, Rapoport B, Ruff P, Slabber CF. Scientific Fraud and International Research. *J Clin Oncol* 19 (15): 3592, 2001
68. Vorobiof DA, Sitas F, Phil D, Vorobiof G. Breast Cancer Incidence in South Africa. *J Clin Oncol*. 19 (suppl.): 125S-127S, 2001
69. Vorobiof DA, Rapoport BL. Phase II Clinical Trial of Carboplatin and Docetaxel in Patients with Metastatic Ovarian Cancer. *Cancer Conference Highlights*. 5 (5): 9-12, 2001
70. Vorobiof DA. Malignant Melanoma – The New Revised Staging System. *S.A. Dermatology Review* 1(4) 43-47, 2001
71. Baum M, Dowsett M, Coibion M, Bianco AR, Cuzick J, George WD, Gray J, Howell A, Houghton J, Williams N, Sloane J, Tobias J, Buzdar A, Anderson MD, Jackson I, Sahnoud T, Gallagher J, Webster A, Gangji D, Petrakova K, Konopasek B, Mares P, Vodvarka P, Alcazar A, Campos O, Maxwell A, Goedhals L, Hacking D, Landers G, Smith L, Vorobiof DA, Werner ID, Blamey R, Coleman R, Grieve RJ, Hickish T, Nicholls JC, Nicholson S, Raymond S, Salman A, Blum J, Clark R, Lyss A, Miletello G, Sternberg J, Forbes J, Nabholz JM, Guastalla JP, Distler W, Klijn JGM, Nagykalnai T, Nicolucci A, Constenla M, Nylen U, Sainsbury R, Mansel RE, Goerge D, Locker GY, Pollard S, Stroner P, Buyse M, Margolese R, and Northover JMA, Pharmacokinetics of anastrozole and tamoxifen alone, and in combination, during adjuvant endocrine therapy for early breast cancer in postmenopausal women: a sub-protocol of the 'Arimidex™ and Tamoxifen Alone or in Combination' (ATAC) trial. *British Journal of Cancer* 85: 317-324, 2001.
72. Vorobiof DA, Rapoport BL, Chasen MR, Abratt RP, Cronje N, Fourie L, McMichael G, Hacking D. Malignant Pleural Mesothelioma : A Phase II Trial with Docetaxel. *Annals of Oncology* 13:412-415, 2002
73. Chasen MR, Vorobiof DA. Chemotherapy in Unresectable Non-Small-Cell Lung Cancer – An Update. *South African Respiratory Journal*, Vol 8, No. 3:136-137, 2002

74. Jean-Marc Nabholz, Carla Falkson, Daniel Campos, Janos Szanto, Miguel Martin, Stephen Chan, Tadeuz Pienkowski, Jerzy Zaluski, Tamas Pinter, Maciej Krzakowski, Daniel Vorobiof, Robert Leonard, Ian Kennedy, Nacer Azli, Michael Murawsky, Alessandro Riva, Pierre Pouillart. Docetaxel and Doxorubicin Compared with Doxorubicin and Cyclophosphamide as First-Line Chemotherapy for Metastatic Breast Cancer: Results of a Randomized, Multicenter, Phase III Trial. *J Clin Oncol* 21(6) 968-975, 2003.
75. Gabriel Vorobiof, Gangaram Hariparsad, Woolf Freinkel, Harry Said, Daniel A Vorobiof. Primary Osteosarcoma of the Breast – A Case Report. *The Breast Journal*, 9(3): 231-233, 2003.
76. Martin R Chasen, Daniel A Vorobiof. Phase II trial of gemcitabine and vinorelbine in patients with stage IIIB and IV non small cell lung cancer. *Rev Oncol*, 5 (1):21-26, 2003.
77. Vorobiof DA, Rapoport BL, Mahomed R, Karime M. Phase II Study of Pegylated Liposomal Doxorubicin in Patients with Metastatic Malignant Melanoma Failing Standard Chemotherapy Treatment. *Melanoma Research*, 13 (2):201-203, 2003.
78. Vorobiof DA, Rapoport BL, Chasen MR, Cohen GL, Mahomed R, Karime M. Phase II Clinical Trial of Carboplatin and Docetaxel in Patients with Metastatic Ovarian Cancer. Active Combination with Low Incidence of Peripheral Neuropathy. *International Journal of Gynecological Cancer*. May-June, 13 (3): 287-29, 2003.
79. Raymond P Abratt, Daniel A Vorobiof. Cancer in Africa. *Lancet Oncol*; 4:394-6, 2003
80. R P Abratt, R Eek, L Goedhals, B Rapoport, C F Slabber, D A Vorobiof. Guidelines for CPD Accreditation of the South African Society of Medical Oncology. *SAMJ* 93 (10): 728, 2003.
81. A. Deverell, D. A. Vorobiof, E. Ross: Psychosocial issues in Cancer. In: Psychosocial approaches to health, illness and disability, E. Ross and A. Deverell (Eds), van Schaik Pubs, Pretoria, 2004, pp 115-132.
82. Vorobiof D A; Rapoport B L; Chasen M R; Slabber C; McMichael G; Eek R and Mohammed C. First line therapy with paclitaxel (Taxol) and pegylated liposomal doxorubicin (Caelyx) in patients with metastatic breast cancer: a multicentre phase II study. *The Breast Vol* 13(3): 219-226, 2004.
83. Michele Ghielmini, Shu-Fang Hsu Schmitz, Sergio B Cogliatti, Gabriella Pichert, Jörg Hummerjohann, Martin F Fey, Daniel C Betticher, Giovanni Martinelli, Fedro Peccatori, Urs Hess, Emanuele Zucca, Roger Stupp, Tibor Kovacsovics, Claudine Helg, Andreas Lohri, Mario Bargetzi, Daniel Vorobiof and Thomas Cerny for the Swiss Group for Clinical Cancer Research (SAKK), Bern, Switzerland. Prolonged treatment with rituximab in patients with follicular lymphoma significantly increases event-free survival and response duration compared with the standard weekly x 4 schedule. *Blood*, Vol. 103, (12): 4416-4423, 2004.
84. Raymond P Abratt, Daniel A. Vorobiof, Neil White. Asbestos and Mesothelioma in South Africa. *Lung Cancer* 45 (1): S3-S6, 2004.
85. Dagmar K Whitaker, Werner Sinclair, Daniel Vorobiof, David Presbury, Peter Scott, Helen Stubbings, Charles Thatcher, A Giraud, Brian Ritchie, Constant Nel, Gary Levy. Guideline on the Management of Melanoma. *SAMJ Vol.* 94, (8) 3: 697-708, 2004.
86. Raymond P Abratt, Neil W White, Daniel A Vorobiof. Epidemiology of mesothelioma – A South African perspective. *Lung Cancer* 49S1, 513-515, 2005.
87. Vorobiof Daniel A. Has there been an improvement in the Medical Management of Breast Cancer? *Menopause Update* 9 (2): 2006.

88. M Campone, H Cortes-Funes, D Vorobiof, M Martin, CF Slabber, E Ciruelos, E Bourbouloux, C Mendiola, FM Delgado, C Colin, V Aslanis and P Fumoleau. Vinflunine: a new active drug for second-line treatment of advanced breast cancer. Results of a phase II and pharmacokinetic study in patients progressing after first-line anthracycline/taxane-based chemotherapy. *British Journal of Cancer* 95 (9): 1161-1166, 2006.
89. Vorobiof Daniel A. Progress in the Medical Treatment of Malignant Pleural Mesothelioma. *Cancer & Chemotherapy Rev*, 1:107-113, 2006.
90. A W Musk, N H de Klerk, Jacek Niklinski, Wieslawa Niklinska, Elzbieta Chyczewska, Jerzy Laudanski, Wojciech Naumnik, Lech Chyczewski, Eric Pluygers, Raymond P Abratt, Daniel A Vorobiof, Neil White, Salih Emri, Murat Tuncer & Izzettin Baris. *Epidemiological Snapshots From Around the World in: Malignant Pleural Mesothelioma*. Eds K O'Byrne and V Rusch, Oxford University Press, 2006.
91. I N Olver, M J Byrne, E Walpole, D Vorobiof, C Jacobs, K Maart, S Hewitt, G McAdam, J C Pouget, M C Pinel. Phase II study of IV vinflunine in patients with chemotherapy naïve metastatic malignant melanoma. *European Journal of Cancer* 43:1829-1832, 2007.
92. Vorobiof DA. Chronic Pain in Oncology. *Pain Update Vol. 1, (2): 7-8*, 2007.
93. Daniel A Vorobiof, Raymond Abratt. The cancer burden in Africa. Editorial. *SAMJ* 97 (10) 937-939, 2007.
94. Prudence Francis, John Crown, Angelo Di Leo, Marc Buyse, Ana Balil, Michael Andersson, Bo Nordenskjöld, Istvan Lang, Raimund Jakesz, Daniel Vorobiof, Jorge Gutiérrez, Guy van Hazel, Stella Dolci, Sophie Jamin, Belguendouz Bendahmane, Richard D. Gelber, Aron Goldhirsch, Monica Castiglione-Gertsch, Martine Piccart-Gebhart. On behalf of the BIG 02-98 Collaborative Group. Adjuvant Chemotherapy With Sequential or Concurrent Anthracycline and Docetaxel: Breast International Group 02-98 Randomized Trial. *J Natl Cancer Inst*, 100:121-133, 2008.
95. Daniel A Vorobiof, Keo Mafafo. Medical Treatment of Early Breast Cancer. *Menopause Update* 11(3): 8-9; 2008.
96. A Eniu, R W Carlson, N S El Saghir, J Bines, N S Bese, D Vorobiof, R Masetti, B O Anderson, on behalf of the Breast Health Global Initiative Treatment Panel. Guideline Implementation for breast healthcare in low- and middle-income countries: Treatment resource allocation. *Cancer* 113 (S8): 2269-2281, 2008.
97. N S El Saghir, A Eniu, R W Carlson, Z Aziz, D Vorobiof, G N Hortobagyi, on behalf of the Breast Health Global Initiative Systemic Therapy Focus Group. Locally Advanced Breast Cancer: Treatment guideline implementation with particular attention to low- and middle-income countries. *Cancer* 113 (S8): 2315-2324, 2008.
98. Daniel A Vorobiof, Keo Mafafo. Malignant Pleural Mesothelioma – Medical Treatment Update. *Clinical Lung Cancer* 10(2): 112-117, 2009.
99. Paul Ruff, D A Vorobiof, J P Jordaan, G S Demetriou, S D Moodley, A L Nosworthy, I D Werner, J Raats, L J Burgess. A randomized, placebo-controlled, double-blind phase 2 study of Docetaxel compared to Docetaxel plus zosuquidar (LY335979) in women with metastatic or locally recurrent breast cancer who have received one prior chemotherapy regimen. *Cancer Chemother Pharmacol* 64: 763-768, 2009
100. BL Rapoport, DA Vorobiof, C Slabber, AS Alberts, HS Hlophe, C Mohammed. Phase II Study of Pegylated Liposomal Doxorubicin and Carboplatin in Patients with Platinum-Sensitive and Partially Platinum-Sensitive Metastatic Ovarian Cancer. *Int J Gynecol Cancer* 19(6): 1137-1141, 2009.

ABSTRACTS

1. Vorobiof D A, Quastel M, Golan H. The immunological response in Digoxin treated patients. First International Congress of Immuno Pharmacology, Brighton, England, July 1980.
2. Falkson G, Falkson H C, Vorobiof D A, Pretorius H, Falkson C B. Phase II study of 4-Epidoxorubicin (IMI 8) in Colorectal Cancer. 13th International Congress of Chemotherapy, Vienna, 1983.
3. Iturralde M, Vorobiof D A, Falkson G. Radionuclide ventriculography for the cardiac evaluation of cancer patients receiving chemotherapy. 10th Faculty day, Univ. of Pretoria, 1984.
4. Falkson G, Vorobiof D A. Esorubicin in advanced Colorectal Cancer. European Conference on clinical Oncology (ECC) 3:12, Stockholm, 1985.
5. Vorobiof D A, Moeken C MM. Advanced Colorectal Cancer:A phase II study of Esorubicin. 11th Faculty day, Univ. of Pretoria, 1985.
6. Vorobiof D A, Falkson G. Advanced Prostate Cancer phase II trial of Buserelin given by nasal spray. 16th National Urological Congress, Bloemfontein, 1986.
7. Vorobiof D A, Falkson G, Coccia-Portugal M A, Terblanche A P S, Falkson H C. Oral Idarubicin in combination with Cytosine-Arabinoside in previously untreated patients with acute Non-Lymphocytic Leukemia. Proc. American Society of Clinical Oncology (ASCO) 7:177, 1986.
8. Falkson G, Vorobiof D A, Falkson H C. Advanced Prostate Cancer:A phase II trial of the Gonadotrophin Releasing Hormone Analogue (GnRHA) Buserelin given by nasal spray. Proc. American Ass. for Cancer Research (AACR 27:117), 1986.
9. Vorobiof D A, Falkson G, Terblanche A P S, Coccia-Portugal M A. Oral Idarubicin and Cytosine-Arabinoside in patients with previously untreated Acute Non-Lymphocytic Leukaemia. XXI Congress of the International Society of Hamatology, Sydney, 1986.
10. Coccia-Portugal M A , Falkson G, Terblanche A P S, Vorobiof D A. Idarubicin orally in combination with Cytosine-Arabinoside in previously untreated patients with Acute Non-Lymphocytic Leukaemia. 14th International Cancer Congress (UICC), Budapest, 1986.
11. Iturralde M P, Vorobiof D A. Radionuclide ventricular function in patients receiving cancer chemotherapy. 2nd Congress of the South African Society of Nuclear Medicine, Cape Town, 1986.
12. Vorobiof D A, Falkson G. A phase II trial of the Gonadotrophin Releasing Hormone Analogue (GnRHA) Buserelin given by nasal spray. 5th NCI/EORTC Congress, Amsterdam, 1986.
13. Iturralde M P, Vorobiof D A. Radionuclide ventricular function assessment in patients receiving cancer chemotherapy. IV world Federation of Nuclear Medicine and Biologic Congress, Buenos Aires, 1986.
14. Alberts A S, Falkson G, Vorobiof D A, Falkson H C. Malignant Mesothelioma:A disease currently unaffected by therapeutic manoeuvres. Proc. ASCO 6:124, 1987.
15. Terblanche A P S, Coccia-Portugal M A, Vorobiof D A. Mitoxantrone:A new drug in the treatment of Acute Leukemia. 13th Faculty day, Univ. of Pretoria, 1987.
16. Vorobiof D A, Coccia-Portugal M A, Terblanche A P S, Falkson G. Mitoxantrone in the treatment of Acute Leukemia. Proc. ECCO 4:169, Madrid, 1987.

17. Vorobiof D A. Interferons: The Pretoria Experience. 1st South African Society of Medical Oncology (SASMO) Congress, Johannesburg, 1987.
18. Vorobiof D A, Falkson G, Falkson H C. CAF + Intranasal Buserelin in the treatment of Premenopausal Metastatic Breast Cancer patients. Proc. ASCO 7:15, 1988.
19. Vorobiof D A, Uys A, Falkson G. A phase II trial of high dose 4-Epidoxorubicin. 2nd SASMO congress, Pretoria, 1988.
20. Vorobiof D A, Falkson H C, Gresse P, Falkson G. CAF + Intranasal Buserelin in the treatment of premenopausal metastatic Breast Cancer patients. 2nd SASMO Congress, Pretoria, 1988.
21. Iturralde M P, Vorobiof D A, Falkson G. Prostate Cancer with bone metastases: Stratification of initial extent of disease. 2nd SASMO Congress, Pretoria, 1988.
22. Falkson G, Vorobiof D A, Swanepoel M A T. A phase II trial of Buserelin given by nasal spray in patients with advanced Prostate Cancer. 2nd SASMO Congress, Pretoria, 1988.
23. Ruff P, Vorobiof D A, Coccia-Portugal M A, Uys A, Falkson G. Oral Idarubicin in combination with Cytosine-Arabinoside and Etoposide in previously untreated patients with Acute Non-Lymphocytic Leukemia. 2nd SASMO Congress, Pretoria, 1988.
24. Vorobiof D A, Swanepoel M A T, Falkson G. Comparison of recombinant Alpha 2B Interferon and DTIC versus DTIC in patients with metastatic Malignant Melanoma. 2nd SASMO Congress, Pretoria, 1988.
25. Coccia-Portugal M A, Falkson G, Vorobiof D A, Uys A. Mitoxantrone in the treatment of Acute Leukemia. 2nd International Symposium in Acute Leukemias, Muster, West Germany, 1989.
26. Vorobiof D A, Falkson, Voges C W. DTIC versus DTIC and recombinant Interferon Alpha 2B in the treatment of patients with advanced Malignant Melanoma. Proc. ASCO 8:284, 1989.
27. Vorobiof D A. Chemotherapy in the treatment of advanced Malignant Melanoma. Annual S A Dermatologic Congress, Diseases of the Skin 3:13, 1989.
28. Vorobiof D A. Biologic Response Modifiers in the treatment of metastatic Malignant Melanoma. Annual SA Dermatologic Congress, Disease of the Skin 3:13, 1989.
29. Vorobiof D A, Falkson G. DTIC versus DTIC and recombinant Interferon Alpha 2B in the treatment of patients with advanced Malignant Melanoma. Proc ECCO 5, London, 1989.
30. Vorobiof D A. Medical treatment of advanced Malignant Melanoma. 13th National Congress of Radiotherapy and Oncology, Transkei, 1990.
31. Vorobiof D A, Seymour L, Ariad S, Bezwoda W. The use of Interferon in the treatment of CML and Myeloproliferative disorders. 3rd SASMO Congress, Stellenbosch, 1990.
32. Bezwoda W, Seymour L, Ariad S, Vorobiof D A. High dose 4-Epiadriamycin as primary treatment for advanced Breast Cancer. Proc. ASCO 10:49, 1991, Houston.
33. Vorobiof D A. Chronophenomena in cancer therapy. 26th SA Pharmacological Society Meeting, San Lameer, Oct. 1991.
34. Vorobiof D A, Zeger A. Mitomycin C, 5-Fluorouracil (5-FU) and Leucovorin (LV) in the treatment of advanced Colorectal Cancers. SASMO/SASRT Congress, Drakensberg, April 1992.

35. Bezwoda W, Vorobiof D A, Ariad S, Spencer D. Vindesine plus Interferon Alpha 2B versus Interferon Alpha 2B versus Vindesine in the treatment of advanced Malignant Melanoma. SASMO/SASRT Congress, Drakensberg, April 1992.
36. Bezwoda W, Seymour L, Vorobiof D A. High dose Cyclophosphamide, Mitoxantrone and VP-16 as first line treatment for metastatic Breast Cancer. Proc. ASCO 11:64, San Diego, 1992.
37. Vorobiof D A. Non-Hodgkin's Lymphoma - unusual clinical presentations. 6th S A Lymphoma Study Group Meeting, Johannesburg, 1992.
38. Vorobiof D A, Bezwoda W, Ariad S. Vindesine plus Interferon Alpha 2B versus Vindesine in the treatment of advanced Malignant Melanoma. ASCO 12:391, 1993.
39. Vorobiof D A, Ansell S M, Blou M. Cyclophosphamide, Vincristine, Epiadriamycin, Prednisone and GM-CSF in the treatment of Non-Hodgkin's Lymphoma. SASMO, 5th Congress, September 1993.
40. Bezwoda W, Vorobiof D A, Ariad S. Vindesine plus Interferon Alpha 2B versus Vindesine in the treatment of advanced Malignant Melanoma. SASMO, 5th Congress, September 1993.
41. Vorobiof D A, Bezwoda W, Dansey R. Metastatic Malignant Melanoma: A randomised trial of Vindesine and Interferon Alpha 2B versus Interferon Alpha 2B versus Vindesine. American Radium Society, 76th meeting, Bermuda, April 1994.
42. Vorobiof D A, Chasen M R. Paclitaxel in the treatment of Advanced Breast and Ovarian Cancers. SASMO/SASRO Congress, September 1995.
43. Vorobiof D A for the S A Taxotere Compassionate Study Programme. Taxotere in the treatment of Refractory Breast Cancer patients. SASMO/SASRO Congress, September 1995.
44. Vorobiof D A, Howell A, Jonat W, Blomqvist C P, Eirman W, Fornader T, Tyrell C, Mauriac L, Walton P from the Arimidex Study Group and Zeneca Pharmaceuticals. Arimidex vs Megestrol Acetate in the treatment of post-menopausal women with advanced Breast Cancer. SASMO/SASRO Congress, September 1995.
45. Gudgeon A, Goedhals L, Smith L, Pervan V, Vorobiof D A. Results of a randomised double blind comparative study of Mitoxantrone, Mitomycin C and Methotrexate (triple M) vs Mitoxantrone, Mitomycin C, Methotrexate and Granulocyte/Macophage Colony Stimulating Factor (triple M plus GM-CSF) in the treatment of 2nd line Advanced Metastatic Breast Cancer. SASMO/SASRO Congress, September 1995.
46. Vorobiof D A, Chasen M R. DTIC, Vinblastine and Interferon Alpha 2B treatment in Metastatic Malignant Melanoma. SASMO/SASRO Congress, September 1995.
47. Ruff, P, Goedhals L, Vorobiof D A, Bloch B, Paska W on behalf of the Ondansetron and Granisetron Emesis Study Group. Ondansetron compared with Granisetron in the prophylaxis of Cisplatin induced acute emesis. SASMO/SASRO Congress, September 1995.
48. Vorobiof D A. The role of chemotherapy in the treatment of head and neck cancer patients. South African Head and Neck Oncology Society Annual Meeting, 27 October 1995.
49. Vorobiof D A for the SA Compassionate Study Group. Taxotere as single agent in the treatment of Advanced Breast Cancer patients refractory to chemotherapy. Taxotere International Symposium, 27 January 1996, Prague.
50. Vorobiof D A, Chasen M R. Paclitaxel in the treatment of refractory Ovarian Cancer patients. SASOG Congress, 24 April 1996, Bloemfontein.

51. Vorobiof D A, Chasen M R, Moeken R. Phase II trial of single agent Docetaxel in previously treated patients with advanced Breast Cancer. ASCO, May 1996, Philadelphia.
52. M Chasen, L Goedhals, D Vorobiof, P Ruff. The Adcock Ingram Trial of Clofazamine in Relapsed Lymphoma. S A Lymphoma Study Group Meeting, September 1996, Cape Town.
53. Dowsett MM, Vorobiof D A, Kleeberg VR, Carrion RP, et al. A randomised blind comparison of estrogen suppression with Arimidex (Anastrozole) and Formestane in post menopausal, advanced Breast Cancer. 19th San Antonio Breast Cancer Symposium, December 1996.
54. Vorobiof D A, Presbury D, Scott P, Giraud A, Thatcher C, Kaplan N, Johnson C on behalf of the the South African Melanoma Advisory Board. The first South African Malignant Melanoma Educational Campaign. SASMO/SASRO Congress, March 1997, Durban.
55. Vorobiof D A, Chasen M R. Single agent Gemcitabine in the treatment of advanced Pancreatic Cancer. SASMO/SASRO Congress, March 1997, Durban.
56. Vorobiof D A, Goedhals L, Barnardt P, Gudgeon A, Van Der Merwe A, Smith L, Murray E, Pretorius D, Bassompierre P, Bergonzoli E, Delgado F M, Le Pape I, Burillon J-P H, Le Couturier S. Phase II study of IV Navelbine and Doxorubicin in previously untreated advanced Breast Cancer. SASMO/SASRO Congress, March 1997, Durban.
57. Gudgeon A, Guastalla J P, Murray R, Piccart M, Van Zyl J, Vorobiof D for the Rivizor™ Study Group. Rivizor™ (Vorzole) versus Aminoglutethimide in the secondline treatment of advanced postmenopausal Breast Cancer. SASMO/SASRO Congress, March 1997, Durban.
58. Vorobiof D A, Dowsett M, Kleeberg U R, Carrion R P, Dodwell D J, Robertson J F R, Calvo L on behalf of the Arimidex Study Group. A randomised blinded comparison of suppression of plasma oestrogens with Arimidex™ (Anastrozole) and Formestane in postmenopausal advanced Breast Cancer (ABC) patients. SASMO/SASRO Congress, March 1997, Durban.
59. Rapoport B L, Goedhals L, Ruff P, Vorobiof D A, Duckworth W. A multicentre, double-blind, double-dummy, randomised parallel group study to compare the efficacy and safety of Ondansetron tablet 8mg BD and Ondansetron Zydis 8mg BD in the control of emesis and nausea induced by Cyclophosphamide-containing chemotherapy treatment in cancer patients. SASRO/SASMO Congress, March 1997, Durban.
60. Vorobiof D A, Bezwoda W, Goedhals L, Van Der Merwe A, Jordaan J P, Barnardt P, Bergonzoli E, Bassompierre P, Delgado M, Le Pape I, Burillion J-P, Danel P, Le Couturier S. Phase II trial of IV Navelbine and Cisplatin in inoperable locally advanced or disseminated Non-Small Cell Lung Cancer: Preliminary results. SASMO/SASRO Congress, March 1997, Durban.
61. Chasen M R, Vorobiof D A. Pilot study in restaging Taxol and Carboplatinum in patients with advanced Ovarian Cancer. SASMO/SASRO Congress, March 1997, Durban.
62. Vorobiof D A, Goedhals L, Barnardt P, Gudgeon A, Van Der Merwe A, Smith L, Murray A, Pretorius D, Bassompierre P, Bergonzoli E, Delgado FM, Le Pape I, Burillion JPh, Le Couturier S. Phase II study of IV Navelbine and Doxorubicin in previously untreated advanced breast cancer. ASCO 16: 197a, 1997 (Abs 693).
63. Chan S, Friederichs K, Noël D, Duarte R, Vorobiof D A, Pinter T, Yelle L, Alaki M, Murawsky M, Riva A. A randomised phase III study of Taxotere versus doxorubicin in patients with metastatic breast cancer who have failed an alkylating containing regimen: preliminary results. ASCO 16: 154a, 1997 (Abs 540).
64. Vorobiof D A, Presbury D, Scott P. The first South African Malignant Melanoma Educational Campaign. 4th World Conference on Melanoma, Sydney, 10-14 June 1997. Melanoma Research 7(1) 581, 1997.

65. Chasen M, Vorobiof D A. Single agent Gemcitabine in the treatment of advanced pancreatic cancer. 35th Annual Congress SAGES 1997. SAMJ 87(6) 760, 1997.
66. Vorobiof D A. New developments in the chemotherapy treatment of Advanced Ovarian Cancer. 6th Gynaecological Cancer Congress, August 1997, South Africa.
67. Vorobiof D.A., Goedhals L., Barnardt P., Gudgeon A., et al. Phase II study of navelbine (NVB) and doxorubicin (DOX) in previously untreated advanced breast cancer. Eur. J. Can. 33(8) 1997 (Abs. 690).
68. L. Goedhals, W. Bezwoda, D. Vorobiof et al. Phase II trial of i.v. navelbine (NVB) and cisplatin (CDDP) in inoperable locally advanced or disseminated NSCLC. Eur. J. Can. 33(8) 1997 (Abs 1082).
69. Chan S, Friederichs K, Noel D, Pinter T, van Belle S, Vorobiof D A, Duarte F, et al. A phase III study of Taxotere vs. Doxorubicin in patients with metastatic breast cancer who have failed an alkylating containing regime. 20th Annual San Antonio Breast Cancer Symposium, December 1997.
70. Goedhals L, Bezwoda W, Vorobiof D A, Van Der Merwe A, Jordaan J P, Barnardt P, Bassompierre P, Lategan A, Burillon J P, Danel P. Phase II trial of IV Navelbine (NVB) and Cisplatin (CDDP) in inoperable locally advanced or disseminated NSCLC. Lung Cancer, 21 (S1), 1998, S34 (Abs).
71. Vorobiof D A. Anastrozole (ArimidexTM) - A new generation in aromatase inhibition: recent data from two clinical studies in postmenopausal women with advanced breast cancer. SASMO/SASRO Congress, October 1998, Cape Town.
72. Vorobiof D A, Chasen M R, Ostria D. Long term prognosis of high risk melanoma patients treated with low dose interferon alpha-2. SASMO/SASRO Congress, October 1998, Cape Town.
73. Callaghan R M, Rapoport B, Vorobiof D A, Brennan S, Landers G, Heslop L, Jacobs C, Van Der Merwe A, Bezwoda W, Falkson C, Pienaar R, Raats J, Jordaan J P. Campto (CPT-II) with or without granulocyte (Lenograstim) in the treatment of metastatic colorectal cancer (MCRC): The South African data. SASMO/SASRO Congress, October 1998, Cape Town.
74. Chasen M R, Vorobiof D A. Tomudex as salvage therapy in patients with advanced gastrointestinal tract cancers. SASMO/SASRO Congress, October 1998, Cape Town.
75. Rapoport B L, Goedhals L, Ruff P, Vorobiof D A. A multicentre, double-blind comparison of intravenous and oral administration of ondansetron plus dexamethasone for acute cisplatin-induced emesis. SASMO/SASRO Congress, October 1998, Cape Town.
76. Vorobiof D A, Ostria D E, Vorobiof G, Chasen M R. Outcome of high risk melanoma patients treated with low dose Interferon alpha 2b, 3rd INTNL Conference on Adj. Therapy of Malignant Melanoma, 19-20 March 1999, London, p22 (Abs P-14).
77. Vorobiof D A. Malignant Lymphomas of the Head and Neck. International Head and Neck Oncology Congress, March 1999, Cape Town, South Africa.
78. Vorobiof D A, Goedhals L, Van Der Merwe A, Jordaan J P, Barnardt P, Lategan A, Burillon J P, Danel P, Gasmi J. Long term survival in Stage IV Non Small Cell Lung Cancer (NSCLC) treated by Vinorelbine and Cisplatin. 35th ASCO Meeting, 15-18 May 1999, Atlanta, USA. (Abs 2031)
79. Nabholz JM, Falkson G, Campos D, Szanto J, Martin M, Chan S, Pienkowski T, Bezwoda WR, Zawski J, Pinter T, Krzakowski M, Vorobiof D A, Leonard R, Kennedy I, Azli N, Murawsky M, Riva A, Poullart P. A Phase III trial comparing Doxorubicin (A) and Docetaxel (T) (AT) to Doxorubicin and Cyclophosphamide (AC) as first line chemotherapy for MBC. 35th ASCO Meeting, 15-18 May 1999, Atlanta, USA, (Abs 485)

80. Naidoo S, Harris L, Vorobiof D A, Chasen MR. Assessment of alternative and complementary medicines and devices in Cancer patients attending a Multidisciplinary Cancer Centre. Nursing Oncology Congress, (Abs P-18) June 1999, Durban, South Africa.
81. Harris L, Naidoo S, Vorobiof D A, Chasen MR. Assessment of alternative and complementary medicines and devices in Cancer patients attending a Multidisciplinary Cancer Centre. Nursing Oncology Congress, ECCO 10, September 1999, Vienna.
82. Ruff P, Moodley SD, Rapoport BL, Chasen MR, Jacobs C, Hacking D and Vorobiof DA. Pegylated Liposomal Doxorubicin (Caelyx) in Advanced Metastatic and Unresectable Hepatocellular Carcinoma. SASMO/SASRO Congress, Pretoria, March 2000.
83. Vorobiof DA, Chasen MR, Pienaar R, Raats J, vd Merwe A, Landers G, Rapoport B, McMichael G, Ruff P, Voges R. Caelyx in the treatment of patients with Advanced Malignant Melanoma, Prostate and Kidney Cancer. SASMO/SASRO Congress, Pretoria, March 2000.
84. Chasen MR, Vorobiof DA. Phase II Trial of Gemzar and Navelbine in the treatment of patients with Stage III B and IV Non-Small Cell Lung Cancer (NSCLC). SASMO/SASRO Congress, Pretoria, March 2000.
85. Vorobiof DA, Chasen MR, Abratt RA, Rapoport BL, Cronje N, Hacking D, Fourie L. A Phase II Trial of Taxotere in Malignant Pleural Mesothelioma. SASMO/SASRO Congress, Pretoria, March 2000.
86. Rapoport BL, Vorobiof DA, Jacobs C, Mahomed R, Uys A. A Phase II Study of Docetaxel (Taxotere®) and Carboplatin in patients with Ovarian Cancer not previously treated with chemotherapy. SASMO/SASRO Congress, Pretoria, March 2000.
87. Rapoport BL, Vorobiof DA, Chasen M, Ruff P, Fourie L, Mohamed R, Uys A. Treatment of Philadelphia Chromosome-Positive early chronic phase. Chronic Myelogenous Leukemia with daily doses of Interferon Alpha and YNK-01 (oral Cytarabine). Preliminary results of a Phase I/II study. The South African CML Study Group. A SASMO CTG Clinical Study. SASMO/SASRO Congress, Pretoria, March 2000.
88. Chasen MR, Lindeque B, Mcloughlim H, Vorobiof DA, Schoeman H. Osteosarcoma – The need for a multi-disciplinary team approach. SASMO/SASRO Congress, Pretoria, March 2000.
89. Naidoo S, Harris L, Vorobiof DA, Chasen M. The use of alternative and complementary therapies in cancer patients attending a private cancer centre. SASMO/SASRO Congress, Pretoria, March 2000.
90. Vorobiof DA, Chasen MR, Abratt R, Rapoport B, Cronje N, Fourie L, McMichael G, Hacking D. Taxotere in malignant pleural mesothelioma. A phase II clinical trial. 9th World Conference on Lung Cancer. September 2000 Tokyo, Japan (Abs 58).
91. Chasen MR, Vorobiof DA. Gemzar and Navelbine in the treatment of patients with stage III b and IV Non-small cell lung cancer. A phase II trial. 9th World Conference on Lung Cancer. September 2000 Tokyo, Japan (Abs 98).
92. Ruff P, Moodley SD, Rapoport BL, Chasen MR, Jacobs C, Hacking D, Vorobiof DA. Phase II study of pegylated liposomal doxorubicin (Caelyx) in advanced hepatocellular carcinoma (HHC). 25th ESMO Congress, Hamburg, Germany. October 2000 (Abs 306P).
93. Hirte H, Vergote I, Jeffrey J, Grimshaw R, Stuart G, Mendiola C, Vorobiof D, Carey M, Coppieters S, Schwartz B, Tu D, Sadura A, Seymour L. NCIC CTG OV12: An international

multicentre phase III study of BAY 12-9566 (BAY) versus placebo in patients (pts) with advanced ovarian cancer (OVCA) responsive to primary surgery/paclitaxel + platinum containing chemotherapy (CT). 25th ESMO Congress, Hamburg, Germany. October 2000 (Abs 714IN).

94. Landers G, Vorobiof DA, Diederiks D, Presbury D. The South African melanoma advisory board (SAMAB) educational campaign: Beach spot checks. *Melanoma Research*, Vol 11, Supp 1, 2001, S146.
95. Vorobiof DA. Clinical Trials in Oncology – A Perspective – Palliative Care Conference, 23-25 April 2001, Johannesburg
96. Vorobiof DA, Chasen MR, Vorobiof G, Rosengarten A. Long term outcome of stage III malignant melanoma patients treated with adjuvant low dose interferon α 2b. *Melanoma Research*, Vol 11, Suppl. 1, 2001, S176.
97. Ruff P, Moodley S, Rapoport B, Vorobiof D, Maart K, Chasen M. Long Term Follow-Up of Pegylated Liposomal Doxorubicin (Caelyx): a Well Tolerated and Effective Agent in Advanced Hepatocellular Carcinoma (HCC). 37th ASCO Meeting 12-15 May 2001, San Francisco, USA (General Poster 667)
99. Hirte HW, Vergote IB, Jeffrey JR, Grimshaw RN, Stuart GC, Mendiola C, Vorobiof DA, Carey MS, Coppieters S, Schwartz B, Tu D, Sadura A, Seymour L. An International Multicentre Phase III Study of BAY 12-9566 (BAY) Versus Placebo in Patients with Advanced Ovarian Cancer Responsive to Primary Surgery/Paclitaxel + Platinum Containing Chemotherapy. 37th ASCO Meeting 12-15 May 2001, San Francisco, USA (General Poster 843)
100. Vorobiof DA, Rapoport BL, Mahomed R, Uys A, Chasen M, Jacobs C. A Phase II First Line Study of Docetaxel and Carboplatin (CBDCA) in Patients with Advanced Ovarian Cancer. 37th ASCO Meeting 12-15 May 2001, San Francisco, USA (General Poster 880)
101. Goedhals L, Gudgeon A, Barnardt P, Vorobiof DA. Navelbine – Doxorubicin Combination as Induction or First Line Chemotherapy in Locally Advanced or Metastatic Breast Carcinoma in South African Patients. 37th ASCO Meeting 12-15 May 2001, San Francisco, USA (Abs 2001)
102. Vorobiof DA, Rapoport BL, Jacobs C, Chasen MR, Eek R, Cohen G, Mahomed R, Uys A. A Phase II First Line Study of Docetaxel and Carboplatin (CBDCA) in Patients with Advanced Ovarian Cancer. SASMO/SASCRO Congress, Misty Hills, September 2001.
103. Hirte HW, Vergote IB, Jeffrey JR, Grimshaw RN, Stuart GC, Mendiola C, Vorobiof DA, Carey MS, Coppieters S, Schwartz B, Tu D, Sadura A, Seymour L. An International Multicentre Phase III Study of BAY 12-9566 Versus Placebo in Patients with Advanced Ovarian Cancer Responsive to Primary Surgery/Paclitaxel + Platinum Containing Chemotherapy. SASMO/SASCRO Congress, Misty Hills, September 2001.
104. Mohammed S, McMichael L, Vorobiof DA, McMichael G, Chasen MR. HER2neu Identification in Breast Cancer Patients Correlation with other Disease Characteristics. SASMO/SASCRO Congress, Misty Hills, September 2001.
105. Rapoport BL, Mahomed R, Slabber C, Vorobiof D, Landers G, Uys A, Raats J. Significant Responses in Patients with Metastatic Breast Cancer Refractory to Anthracycline and Taxane Therapy. Results of a Phase I/II Clinical Trial of Cisplatin, and Raltitrexed (Tomudex®). SASMO/SASCRO Congress, Misty Hills, September 2001.
106. Harris L, Vorobiof DA, McMichael G, Chasen MR. CPT11 Combination Therapy in the Treatment of Advanced Colorectal Cancer. SASMO/SASCRO Congress, Misty Hills, September 2001.

107. Rapoport BL, Vorobiof DA. Safety of Caelyx in Solid Tumours. SASMO/SASCRO Congress, Misty Hills, September 2001.
108. Vorobiof DA, Rosengarten A, Callaghan R, Rapoport B, Jacobs C, McMichael G. Caelyx for Recurrent / Relapsed Ovarian Cancer. SASMO/SASCRO Congress, Misty Hills, September 2001.
109. Ruff P, Moodley SD, Rapoport BL, Vorobiof DA, Maart K, Chasen MR. Long Term Follow-up of Pegylated Liposomal Doxorubicin (Caelyx): A Well Tolerated and Effective Agent in Advanced Hepatocellular Carcinoma. SASMO/SASCRO Congress, Misty Hills, September 2001.
110. Rapoport BL, Vorobiof DA, Chasen MR, McMichael G, Cohen G, Eek R, Mahomed R, Uys A, Jacobs C. Low Incidence of Neurotoxicity in Patients Undergoing Chemotherapy With Docetaxel and Carboplatin: Results of a Phase II First Line Study in Advanced Ovarian Cancer. 38th ASCO Meeting 18-21 May 2002, Orlando, Florida, USA (General Poster 862).
111. Mahomed R, Rapoport BL, Slabber CF, Vorobiof DA, Landers G, Uys A, Raats J. Significant Responses with Cisplatin Based Therapy in Patients with Metastatic Breast Cancer Refractory to Anthracycline or Anthracycline and Taxanes: Results of a Phase VII Trial of Cisplatin and Raltitrexed. 38th ASCO Meeting 18-21 May 2002, Orlando, Florida, USA (Abstract 1999).
112. Vorobiof DA, Rapoport BL, McMichael GB, Chasen MR, Eek R, Mohammed C. Paclitaxel and Pegylated Liposomal Doxorubicin as First Line Therapy for Patients with Metastatic Breast Cancer. 38th ASCO Meeting 18-21 May 2002, Orlando, Florida, USA (Abstract 2062).
113. Ghielmini M, Hsu Schmitz SF, Cogliatti SB, Pichert G, Fey M, Betticher D, Martinelli G, Peccatori F, Hess U, Stahel R, Zucca E, Stupp R, Kovacsovics T, Helg C, Lohri A, Bargetzi M, Vorobiof D, and Cerny Th, for the Swiss Group for Clinical Cancer Research (SAKK), Bern, Switzerland. Maintenance Treatment With 2-monthly Rituximab After Standard Weekly X 4 Rituximab Induction Significantly Improves Event-Free Survival in Patients with Follicular Lymphoma. Annals of Oncology, Vol 13, (Supp 2), 112, 2002. (Abstract 112)
114. Vorobiof DA. Malignant Pleural Mesothelioma. IOF Meeting, Madrid, Spain. September 20-23, 2002.
115. Rabia Mahomed, Bernardo L Rapoport, Coenraad Slabber, Daniel Vorobiof, Greg Landers, Almarie Uys, Johannes Raats. Significant responses in patients with metastatic breast cancer refractory to anthracycline and taxane therapy. Results of a phase I/II clinical trial of cisplatin and raltitrexed. Annals of Oncology, Vol 13, (Supp 5) 27th ESMO Congress October 2002 (Abstract 204P).
116. Daniel A. Vorobiof, Bernardo L Rapoport, Martin R Chasen, Gary B McMichael, Cheryl Mohammed. Phase II trial of pegylated liposomal doxorubicin and paclitaxel as first line therapy for patients (pts) with advanced breast cancer (ABC). Annals of Oncology, Vol 13, (Supp 5) 27th ESMO Congress October 2002 (Abstract 247).
117. Bernardo L Rapoport, Daniel A Vorobiof, Martin Chasen, Richard Eek, Graham Cohen, Rabia Mahomed, Almarie Uys, Conrad Jacobs. A Phase II first line study of docetaxel and carboplatin (CBDCA) in patients with advanced ovarian cancer. An active combination associated with low incidence of peripheral neuropathy. Annals of Oncology, Vol 13, (Supp 5) 27th ESMO Congress October 2002 (Abstract 416).
118. Vorobiof DA. Postoperative Chemotherapy in Early Breast Cancer. Learning from International Consensus. European School of Oncology Congress on Current Breast Cancer Management – November 22-23, 2002

119. Michele Ghielmini, Shu-Fang Hsu Schmitz, Sergio Cogliatti, Gabriella Pichert, Martin Fey, Daniel Betticher, Giovanni Martinelli, Fedro Peccatori, Urs Hess, Rolf Stahel, Emanuele Zucca, Roger Stupp, Tibor Kovacsovics, Claudine Helg, Andreas Lohri, Mario Bargetzi, Daniel Vorobiof, Thomas Cerny. Lymphoma Working Group, Swiss Group for Clinical Cancer Research (SAKK), Bern, Switzerland. Prolonged Treatment with Rituximab Significantly Improves Event Free Survival and Duration of Response in Patients with Follicular Lymphoma: A Randomised SAKK Trial. Blood 100 (11) p161a, Abstract # 604.
120. Chasen MR, Vorobiof DA, McMichael G, Karime M. Trastuzumab use in patients with recurrent metastatic Breast Cancer. SASCRO/SASMO, Bloemfontein, March 2003. Abstract # 3.
121. L Campbell-Gillies, M R Chasen, D A Vorobiof, R W Eek, G L Cohen. The effect of guided imagery as an intervention technique on levels of anxiety & depression in women with Breast Cancer. SASCRO/SASMO, Bloemfontein, March 2003. Abstract # 6.
122. Vorobiof DA, Rapoport BL, Chasen MR, McMichael GB, Eek R, Slabber C, Mohammed C. Phase II Trial of Pegylated Liposomal Doxorubicin and Paclitaxel as first line therapy for patients with advanced Breast Cancer. SASCRO/SASMO, Bloemfontein, March 2003. Abstract # 7.
123. Mahomed R, Rapoport BL, Slabber C, Vorobiof D, Landers G, Uys A, Raats J. Significant responses in patients with metastatic Breast Cancer refractory to anthracycline and taxane therapy. Results of a Phase I/II clinical trial of Cisplatin and Raltitrexed. SASCRO/SASMO, Bloemfontein, March 2003. Abstract # 8.
124. Munisamy S, Vorobiof DA, Chasen MR. Capecitabine (Xeloda) in the treatment of advanced Gastrointestinal Cancers. SASCRO/SASMO, Bloemfontein, March 2003. Abstract # 13.
125. Vorobiof DA, Abratt R. Asbestos and its association to Malignant Mesothelioma: A review of its history and epidemiology. SASCRO/SASMO, Bloemfontein, March 2003. Abstract # 17.
126. Rapoport BL, Vorobiof DA, Mahomed R, Uys A, Slabber C, Alberts AS, Mare R. A Phase II study of Caelyx® and Carboplatin in patients with extensive stage Small Cell Lung Cancer. SASCRO/SASMO, Bloemfontein, March 2003. Abstract # 20.
127. Harris L, Vorobiof DA, Callaghan R, Chasen MR, Jacobs CR, Abratt R, McMichael GB. SASCRO/SASMO, Bloemfontein, March 2003. Abstract # 63.
128. D A Vorobiof. Zometa in Bone Metastases. SASCRO/SASMO, Bloemfontein, March 2003.
129. D A Vorobiof, B L Rapoport, R Mahomed, A Uys, A S Alberts, G L Cohen, R Eek, M R Chasen, C F Slabber, J I Raats. Phase II Study of Combination Therapy with Caelyx™ and Carboplatin in Patients with Relapsed, Platinum-Sensitive Ovarian Cancer (DFI >6 months). Caelyx Investigators' Forum, 3-5 April 2003, Cannes, France. (Poster)
130. D A Vorobiof, M R Chasen, G B McMichael, C Mohammed, B L Rapoport, R Eek, C Slabber. Multicenter Phase II Study with Caelyx™ and Paclitaxel (Taxol®) as First-Line Therapy in Patients with Advanced Breast Cancer. Caelyx Investigators' Forum, 3-5 April 2003, Cannes, France. (Poster)
131. D A Vorobiof. Trastuzumab in the treatment of solid tumours. 1st Roche Oncology Symposium – Treatment Strategies for Future Care. 25-27 April 2003, Zimbali, South Africa.
132. D A Vorobiof, M R Chasen, G B McMichael C Mohammed, B L Rapoport, R Eek, C Slabber. Multicentre phase II study with pegylated liposomal doxorubicin and paclitaxel as first line therapy in patients with advanced breast cancer. 39th ASCO Meeting May 31-June 3, 2003, Chicago, Illinois, USA (Abstract 195)

133. D A Vorobiof, M Aapro. Adjuvant chemotherapy in the elderly population with Breast and Colorectal Cancers. University of Witwatersrand 7th Annual National Symposia, August 2003.
134. D A Vorobiof, B L Rapoport, R Mahomed, et al. A phase II second line study of liposomal doxorubicin and Carboplatin in patients with recurrent ovarian cancer with a disease free interval equal or greater than 6 months. ECCO 12 September 2003, Copenhagen, Sweden.
135. Campone M, Vorobiof D, Cortes Funes H, Verrill M, Khoo Kei S, Slabber CF, Caroff I, Pouget JC, Fumoleau P. Preliminary results of a phase II study of intravenous (IV) vinflunine (VFL) as second line therapy in patients with metastatic breast cancer (MBC) after anthracycline-taxane based regimens failure. 26th San Antonio Symposium on Breast Cancer, December 2003. (Abstract #355)
136. D A Vorobiof Progress in the medical management of malignant mesothelioma. 15th International Congress on Anti-Cancer Treatment, 9-12th February 2004, Paris, France.
137. Daniel A Vorobiof, Bernardo L Rapoport, Coenraad Slabber, et al. Combination therapy with encapsulated liposomal doxorubicin and carboplatin in patients with platinum sensitive recurrent ovarian cancer – A National Phase II Study. ESMO 2004.
138. P. Fumoleau, M. Campone, D. Vorobiof, M. Casado, et al. Phase II study of i.v. vinflunine as second line in patients with metastatic breast cancer after anthracycline-taxane failure. 40th ASCO Meeting, June 5-8, 2004, New Orleans, LA, USA (Poster).
139. D. A. Vorobiof, B. Rapoport, C. Slabber, R. Eek, G. Cohen, A. S. Alberts, G. B. McMichael, J. Raats, A. Uys. Phase 2 study of combination therapy with liposomal doxorubicin and Carboplatin in patients with relapsed, platinum sensitive ovarian cancer. 40th ASCO Meeting, June 5-8, 2004, New Orleans, LA, USA (General Poster).
140. B. L. Rapoport, C. Slabber, D. A. Vorobiof, A.S. Alberts, A. Uys. Phase II study of combination therapy with liposomal doxorubicin and carboplatin in patients with previously untreated small cell lung cancer. 40th ASCO Meeting, June 5-8, 2004, New Orleans, LA, USA (Abstract 7349).
141. Daniel A Vorobiof, Bernardo L. Rapoport, Coenraad Slabber, Richard Eek, Graham Cohen, Almarie Uys. Combination therapy with encapsulated liposomal doxorubicin and carboplatin in patients with platinum sensitive recurrent ovarian cancer – A national phase II study. Annals of Oncology. Vol 15 (Supp 3) 29th ESMO Congress October 2004 (Abs. 481P)
142. Rapoport BL, Slabber CF, Cohen G, McMichael G, Alberts AS, Vorobiof DA. Phase II study of combination therapy with CHOP Interferon (IFN) α 2a and Rituximab ® in chemo-naïve patients (pts) with diffuse large B cell non-Hodgkin's lymphoma (NHL). 41st ASCO Meeting, May 13-17 2005, Orange County Convention Centre, Orlando, Florida, USA (Abstract 6694).
143. D.A. Vorobiof, B.L. Rapoport, C.F. Slabber, A.S. Alberts, A. Uys. A phase II study of combination therapy with liposomal doxorubicin and Carboplatin (CBDCA) in patients (pts) with previously untreated small cell lung cancer (SCLC). 41st ASCO Meeting, May 13-17 2005, Orange County Convention Centre, Orlando, Florida, USA (Abstract 7279).
144. Rapoport BL, Vorobiof DA, Cohen G, Alberts AS, Slabber CF, Raats JI, McMichael GB, Uys A. A phase II study of combination therapy with liposomal doxorubicin (Caelyx®) and Carboplatin (CBDCA) in patients with relapsed, platinum sensitive ovarian cancer. Schering-Plough CAELYX International Update Meeting (IRUM) Baveno, Italy, April 2006.
145. DA Vorobiof. Primary chemotherapy and the role for adjuvant chemotherapy in early non-seminoma testicular cancer. SIU – 28th Congress of the Societe Internationbale d'Urologie, Cape Town, 12-16 November 2006
146. DA Vorobiof. Chemotherapy management of metastatic non-seminoma testicular cancer. SIU – 28th Congress of the Societe Internationale d'Urologie, Cape Town, 12-16 November 2006

147. DA Vorobiof. Pregnancy and Cancer. Multidisciplinary Approach to Gynaecological Cancers. Sandton Convention Centre, Johannesburg -17-18 November 2006.
148. DA Vorobiof. Adjuvant Therapy in Early Breast Cancer. SASCRO / SASMO Congress 2007. Champagne Sports Resort, Drakensburg – 27 April-01 May 2007.
149. DA Vorobiof, BL Rapoport, HS Hlope, CF Slabber, AS Alberts. Phase II study of first line combination therapy with pegylated liposomal doxorubicin and Carboplatin in patients with extensive disease small cell lung cancer. 44th ASCO Meeting, May 30-June 3 2008, Chicago, Illinois, USA (Abstract 19089).
150. BL Rapoport, D Vorobiof, C Slabber, G Cohen, A Alberts, H Hlophe. Phase II study of combination therapy with pegylated liposomal doxorubicin and Carboplatin in patients with relapsed, platinum sensitive and platinum semi-sensitive ovarian cancer. 44th ASCO Meeting, May 30-June 3 2008, Chicago, Illinois, USA (Abstract 5555).
151. DA Vorobiof. How much benefit should there be to justify reimbursement of new cancer drugs? UICC 08 World Cancer Congress. 27-31 August 2008, Geneva, Switzerland.
152. DA Vorobiof. Primary Hepatocellular Carcinoma in the 21st Century - Update on Systemic Therapy. UICC 08 World Cancer Congress. 27-31 August 2008, Geneva, Switzerland.
153. DA Vorobiof. Systemic Therapy of Early Breast Cancer. Controversies and Problems in Surgery Symposium. 3-4 October 2008, University of Pretoria. (Page 35-40).
154. DA Vorobiof. Progress in the Management of Malignant Pleural Mesothelioma. 20th ICACT – International Congress on Anti-Cancer Treatment. 3rd-6th February 2009. Paris, France.
155. CJ Taverna, S Bassi, F Hitz, W Mingrone, T Pabst, L Cevreska, A del Giglio, DA Vorobiof, M Simcock, M Ghielmini. First results of long term Rituximab maintenance treatment in follicular lymphoma: Safety analysis of the randomized phase III trial SAKK 35/03. 45th ASCO Meeting. May 29-June 2 2009, Orlando, Florida, USA (Abstract 8534).
156. F Hitz, S Bassi, C Taverna, W Mingrone, T Pabst, L Cevreska, A Del Giglio, D A Vorobiof, M Simcock, M Ghielmini. First results of long term Rituximab maintenance treatment in follicular lymphoma: Safety analysis of the randomized phase III trial SAKK 35/03. E H A, 4-7th June 2009 (Abstract 0413).
157. G Martinelli, S F Hsu Schmitz, U Hess, E Okkinga, R Stupp, C Taverna, D Vorobiof, M Heizmann, P Y Dietrich, M Ghielmini. Long-term follow-up of follicular lymphoma (FL) patients receiving single agent rituximab at two different schedules in trial SAKK 35/98. European Journal of Cancer Supplements, Vol 7 No 2, September 2009, Page 561.
158. D Vorobiof. Metastatic Breast Cancer: who benefits from Bevacizumab? UICC 10 World Cancer Congress 18-21 August 2010, Shenzhen, China.

EDITORIAL BOARD

- Editor : “Understanding Oncology” - 1/1990 - 12/1997
 “Practical Oncology Forum” (Medical Chronicle) 1998 / 2004
 Specialist Medicine / Oncology 1998 – 2001
 Annals of Oncology – Southern African Excerpts 2004 – to date
- Editorial Advisory Board: Medical Chronicle 1999 – to date
 S.A. Dermatology Review 2001 – 2005
 Annals of Oncology
 Supportive and Palliative Cancer Care Journal
 The Breast
 Cancer & Chemotherapy Reviews
- Associate Editor: Annals of Oncology 2008-2011

CHAIRMANSHIPS

- 1996-2000 Chairman of the South African Melanoma Advisory Board
 1998-2002 Chairman, South African Society of Medical Oncology (SASMO)
 2002-2005 Re-elected Chairman SASMO

BOOKS

1. “INTRON A”. A summary of clinical trials with Interferon Alpha 2B. Edited:1989, 1990 and 1992.
2. Health, illness and disability. Psychosocial approaches. Eleanor Ross, Andee Deverell. Psychosocial issues in cancer – Daniel Vorobiof co-authored sections 8.2-8.6. First edition 2004, Second edition 2010.

MEDICAL EDUCATIONAL BROCHURES, EDUCATIONAL VIDEOS AND TAPES

Interferon Alpha 2B. In collaboration with Prof. E Borden (USA) and Dr J Scarffe(UK), 1986
 Biologic Response Modifiers, 1989
 Lung Cancer, 1990
 Prostate Cancer, practical advice to help you lead a normal life, 1990
 Cancer and chemotherapy - an explanation of the disease and it's treatment for the patient, 1993.
 Breast Cancer - an explanation of the disease and it's treatment for the patient, 1993.
 Taxotere, a new anti-cancer drug, 1995
 Management of Cancer pain, 1995
 Malignant Melanoma, Medical Chronicle, 1998
 Breast Cancer, general information and special issues, Medical Chronicle 1998
 Cancer Management, Cancer Association of SA (CANSA), 2004

CO-OPERATIVE ONCOLOGY GROUPS AFFILIATION

1981 - 1988	Eastern Cooperative Oncology Groups (ECOG)
1995 - to date	International Breast Cancer Study Group (IBCSG)
1996 - 2000	Principal Investigator of the National Advanced Melanoma Study Group
1998 - 2001	Member Executive Committee South African Society of Medical Oncology - Clinical Trials Group (SASMO - CTG)
1998 - to date	WHO Melanoma Programme
2000	EORTC Melanoma
2000	SAKK Lymphoma Study Group (inc. IELSG)
2004 - 2007	Director, South African Oncology Consortium

CONGRESS ORGANISATION

Scientific Convenor of the South African Society of Medical Oncology Congress, March 1997
 Scientific Convenor of the 1st ESO-SASMO Educational Meeting, November 2002
 Scientific Convenor of the 1st Roche Oncology Symposium, April 2003
 Scientific Committee of the 15th ICACT, Paris, France, February 2004
 Scientific Convenor of the 2nd ESO-SASMO Educational Meeting. Johannesburg, November 2004
 Scientific Committee of the 2nd Roche Oncology Symposium, April 2005
 Scientific Convenor of the 3rd Roche Oncology Symposium, August 2006
 Scientific Convenor of the 3rd ESO-SASMO-ESMO Educational Meeting, Johannesburg, Nov. 2006

MEMBERSHIPS

Founder member of the South African Society of Medical Oncology (SASMO)
 Member of the South African Breast Cancer Study Group
 Member of the South African Lymphoma Study Group
 Member of the American Society of Medical Oncology (ASCO), USA
 Member of the European Society of Medical Oncology (ESMO)
 Member of the Gynaecologic-Oncologic Group of South Africa
 Member of the New York Academy of Sciences, USA
 Member of the Medical Association of South Africa (MASA)
 Past Executive Committee Member of the National Cancer Association of South Africa,
 Southern Transvaal Branch
 Member of the Gynaecology Oncology Group of the University of Witwatersrand
 Executive committee member of the South African Society of Medical Oncology
 Member of the International Breast Cancer Study Group (IBCSG)
 Member of the South African Oncology Consultative Committee (SAOC)
 Member of The Chemotherapy Foundation, USA
 Member of The American Society of Breast Diseases
 Founder Member of the International Oncology Foundation
 Member of the Educational Board, Faculty of 1000, Oncology Faculty

PATIENTS ADVOCACY AND AWARENESS PROGRAMMES

Malignant Melanoma 1996-2000 – Mole Patrol Campaign
 Moments in Time, Trustee, 2003-2008
 Prostate Cancer Foundation, Non-Executive Director, 2006 – 2009

